Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage

Liver Transplantation

Volumn 10, Issue 6, 2004, Pages 728-733

  Liu, Chi Leung ^a   Fan, Sheung Tat ^a   Lo, Chung Mau ^a   Chan, See Ching ^a   Ng, Irene O ^a   Lai, Ching Lung ^a   Wong, John ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; ANTIULCER AGENT; BASILIXIMAB; CHOLESTEROL; CORTICOSTEROID; COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; HEPATITIS B ANTIBODY; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISOLONE; STEROID; TACROLIMUS; VIRUS ANTIGEN;

ABDOMINAL ABSCESS; ABDOMINAL BLEEDING; ACUTE GRAFT REJECTION; ADULT; AGED; ANTIGEN DETECTION; ARTERY THROMBOSIS; ARTICLE; BILIARY TRACT DISEASE; CADAVER DONOR; CANCER RECURRENCE; CENTRAL PONTINE MYELINOLYSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAND MAL SEIZURE; HEMOLYSIS; HEPATITIS B; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INGUINAL HERNIA; INTRAOPERATIVE PERIOD; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; LUNG EDEMA; LUNG INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OPEN STUDY; OUTCOMES RESEARCH; PLEURA EFFUSION; PORTAL VEIN THROMBOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; REPERFUSION; STANDARD; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 2942726371     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20144     Document Type: Article

References (25)

1. Padbury RT, Toogood GJ, McMaster P. Withdrawal of immunosuppression in liver allograft recipients. Liver Transpl Surg 1998;4:242-248.
2. Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997;64:1755-1760.
3. Tisone G, Angelico M, Palmieri G, Pisani F, Anselmo A, Baiocchi L, et al. A pilot Study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999;67:1308-1313.
4. Farges O, Saliba F, Farhamant H, Samuel D, Bismuth A, Reynes M, Bismuth H. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology 1996;23:240-248.
5. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995;22:36-43.
6. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334: 815-820.
7. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000;69:1867-1872.
8. Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001;233:276-281.
9. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
10. Moser MA. Options for induction immunosuppression in liver transplant recipients. Drugs 2002;62:995-1011.
11. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-142.
12. Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002;8:123-131.
13. Padbury RT, Gunson BK, Dousset B, Hubscher SG, Buckels JA, Neuberger JM, et al. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation 1993;55:789-794.
14. Canzanello VJ, Textor SC, Taler SJ, Schwartz LI, Porayko MK, Wiesner RH, Krom RA. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg 1998;4:328-334.
15. Busuttil RW, Holt CD. Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Transplant Proc 1997;29: 534-538.
16. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-906.
17. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-626.
18. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:1842-1847.
19. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998;227:841-850.
20. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000;70:809-815.
21. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585-589.
22. Lo CM, Fung JT, Lau GK, Liu CL, Cheung ST, Lai CL, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37:36-43.
23. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
24. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5:S107-S114.
25. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8:S19-S27.